Marie Bosslett, Assistant Editor

Australian researchers found 5-FU to be the cheapest AK treatment, compared to imiquimod and MAL-photodynamic therapy.

A novel study assessed the potential of 2 AI platforms in providing accurate information to patients with HS.

Patients with moderate to severe atopic dermatitis saw the most improvement after taking 600 mg of tozorakimab.

Zirwas spoke with Dermatology Times to share the top clinical pearls and key takeaways from his discussion on contact dermatitis.

The target action date for the FDA decision is April 18, 2025.

Zirwas presented 2 sessions at SDPA on innovative care strategies for patients with AD and other itch-related diseases.

November is Hyperhidrosis Awareness Month - test your knowledge on the subject.

A 12-week regimen showed significant reductions in wrinkle severity and pigment improvement.

November is Hyperhidrosis Awareness Month - test your knowledge on the subject.

Jamie Restivo, MPAS, PA-C, shares some insights from the 5th Annual Keystone Dermatology Conference held from October 17 to 19 in Philadelphia, Pennsylvania.

David M. Pariser, MD, FACP, FAAD, secretary and a founding board member of the International Hyperhidrosis Society, discussed the latest in hyperhidrosis research and the organization’s commitment to helping clinicians treat the condition.

The novel systemic review compared results and adverse events associated with various treatment methods.

These findings can help clinicians better treat the psychosocial factors associated with the disease.

A post hoc analysis of OLYMPIA 1 and 2 trial data found significant improvement in the first 14 days of treatment.

4 case histories highlight the physical and psychosocial burden of generalized pustular psoriasis.

The LIBERTY-AD PED-OLE study showed clinical remission for moderate to severe atopic dermatitis.

The minocycline hydrochloride extended release capsules (40 mg) represent a new standard of care for patients with rosacea.

Clinical trial exit interviews reveal detailed perspectives on disease burden for patients with chronic hand eczema.

VYNE Therapies announces that aNSV patients saw disease improvement without serious adverse effects.

The phase 2a trial demonstrated the systemic treatment’s tolerable safety profile for patients with chronic and progressive hair loss.

A pilot study monitored the disease management, technical challenges, and overall benefits for chronic spontaneous urticaria.

The nonsteroid 1% cream treatment demonstrated good response and tolerability in patients with PPP.

The trial results indicated improved disease control, integrity of skin barrier, and minimal reactions for patients with rosacea.

This review of the latest dermatologic studies includes discussions on the relationship between atopic dermatitis and prurigo nodularis, the use of upadacitinib for treating PN, and more.

The clinical trial showed promising results for patients who used probiotics as an accompanying treatment.

This review of the latest dermatologic studies includes discussions on the development of the Hand Eczema Impact Scale, the role of tofacitinib on Th1 and Th2 cytokines, and more.

The late-breaking data will be presented at ACAAI’s annual Scientific Meeting.

Survey results presented at ACAAI’s annual Scientific Meeting demonstrate the limited influence of elimination diets for reducing symptoms of AD.

Click here to answer today’s poll and read more about the perception of telehealth treatment in dermatology.

The multicenter trial reported high response rates and low risk of discontinuation for treating long-term chronic inducible urticaria.